Ubisoft: Tencent's €1.16 Billion Lifeline Erases Debt, But The Turnaround Still Isn't Proven

Ubisoft: Tencent's €1.16 Billion Lifeline Erases Debt, But The Turnaround Still Isn't Proven

Ubisoft Entertainment (OTCPK:UBSFY) (OTCPK:UBSFF) erased its net debt through Tencent’s €1.16B investment, but its turnaround remains unproven as execution risk and portfolio dependence persist.

Read More
Capcom: Record First-Half Profitability, Sector-Low Valuation, And 40% Upside (Rating Upgrade)

Capcom: Record First-Half Profitability, Sector-Low Valuation, And 40% Upside (Rating Upgrade)

Capcom’s (OTCPK:CCOEY) (OTCPK:CCOEF) 2025 first-half earnings delivered record profitability, sector-low valuation metrics, and accelerating catalog sales. My analysis breaks down why the stock offers 40% upside for long-term investors.

Read More
Niagen Bioscience: A Breakout Quarter That Now Faces Its Biggest Market Shift In Years
Stock Analysis, Healthcare, Life Sciences Tools and Services Alexander I. Velasquez Stock Analysis, Healthcare, Life Sciences Tools and Services Alexander I. Velasquez

Niagen Bioscience: A Breakout Quarter That Now Faces Its Biggest Market Shift In Years

Niagen Bioscience (NASDAQ:NAGE) Q3 2025 earnings delivered explosive growth in revenue, margins, and cash flow—just as NMN re-enters the NAD+ market. Here’s what investors need to know about this new competitive pressure.

Read More